HomeProductsBioactive CompoundsGPCR & G Protein TargetsCaSRCinacalcet
Chemical structure of CAS 226256-56-0

Cinacalcet

In Stock•Starting at $14 for 250 mg•Purity ≥ 98%
CAS No.226256-56-0
MDL No.MFCD09840270
MFC22H22F3N
MW357.40
InChI KeyVDHAWDNDOKGFTD-MRXNPFEDSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
250 mg98%$14In Stock
1 g98%$40In Stock
5 g98%$156In Stock
10 g98%$303In Stock
15 g98%$438In Stock
25 g98%$621In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Cinacalcet is (1R)-1-(naphthalen-1-yl)ethanamine with one hydrogen on the nitrogen replaced by a 3-[3-(trifluoromethyl)phenyl]propyl group. It functions as a calcimimetic and P450 inhibitor, and belongs to naphthalenes, secondary amines, and (trifluoromethyl)benzenes.

CAS No.226256-56-0
Product NameCinacalcet

Biological Targets

CASR

Associated Conditions

renal osteodystrophy·Hypercalcemia·prostate adenocarcinoma·hyperparathyroidism·parathyroid disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.

Kidney international • Vol. 63, Issue 1 • 2003
PMID: 12472790DOI: 10.1046/j.1523-1755.2003.00720.x

Cinacalcet: Amg 073, calcimimetics--Amgen/NPS Pharmaceuticals.

Drugs in R&D • Vol. 4, Issue 1 • 2003
PMID: 12568635DOI: 10.2165/00126839-200304010-00006

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

Journal of the American Society of Nephrology : JASN • Vol. 14, Issue 3 • 2003
PMID: 12595492DOI: 10.1097/01.asn.0000050224.03126.ad

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology • Vol. 25, Issue 4 • 2003
PMID: 12808477

Documentation

Similar Products